Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | -12.9% | 18.3% | 100.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 50.7% | 47% | 61.2% | 69% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $2 | $1 | $1 | $2 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -258.8% | -181.4% | -228.5% | -565.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -282.5% | -192.9% | -236% | -574.5% |
| EPS | -0.2 | -0.16 | -0.17 | -0.2 |
| % Growth | -25% | 5.9% | 15% | – |
| EPS Diluted | -0.2 | -0.16 | -0.17 | -0.2 |
| Weighted Avg Shares Out | 7 | 7 | 7 | 7 |
| Weighted Avg Shares Out Dil | 7 | 7 | 7 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -255.9% | -178.4% | -226.2% | -563.1% |